Cargando…
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors
Mutations in the isocitrate dehydrogenase-1 and -2 (IDH1/2) genes were first identified in glioma and acute myeloid leukemia (AML), and subsequently found in multiple other tumor types. These neomorphic mutations convert the normal product of enzyme, α-ketoglutarate (αKG), to the oncometabolite 2-hy...
Autores principales: | Sule, Amrita, Van Doorn, Jinny, Sundaram, Ranjini K, Ganesa, Sachita, Vasquez, Juan C, Bindra, Ranjit S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127964/ https://www.ncbi.nlm.nih.gov/pubmed/34027408 http://dx.doi.org/10.1093/narcan/zcab018 |
Ejemplares similares
-
Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma
por: Ganesa, Sachita, et al.
Publicado: (2022) -
The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability
por: Mars, Jean-Clément, et al.
Publicado: (2020) -
Synthetic circular miR-21 RNA decoys enhance tumor suppressor expression and impair tumor growth in mice
por: Müller, Simon, et al.
Publicado: (2020) -
A novel siRNA–gemcitabine construct as a potential therapeutic for treatment of pancreatic cancer
por: Simonenko, Vera, et al.
Publicado: (2020) -
Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenoviruses
por: Núñez-Manchón, Estela, et al.
Publicado: (2021)